Insights on increasing the translational value of your preclinical development program.
Jul 14, 2026by MD Biosciences
AAALAC accreditation carries practical weight in preclinical drug development, and its implications for program quality...
Jul 7, 2026by MD Biosciences
Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications...
Jun 30, 2026by MD Biosciences
Spinal cord injury presents one of the most challenging translational profiles in central nervous system drug...
Jun 23, 2026by MD Biosciences
GLP-1 receptor agonists have substantially reshaped the therapeutic landscape for type 2 diabetes and obesity, and the...
Jun 16, 2026by MD Biosciences
Drug development for chronic kidney disease has entered a more ambitious phase. SGLT2 inhibitors, non steroidal...
.png?width=1330&height=748&name=Webinar%20Socials%20(8).png)
.png?width=1332&height=748&name=Webinar%20Socials%20(5).png)
.png?width=800&height=924&name=POP%20in%20pigs%20webinar%20(1).png)
